UPC CFI 701/2024
19. Nov. 2024·EP2077811 · CLAY-BASED HEMOSTATIC AGENTS AND DEVICES FOR THE DELIVERY THEREOF
Hauptaktenzeichen: ACT 61342/2024
- Verfahrensdetails
- StatusCase ClosedVerfahrensartEinstweilige VerfügungKategorieEinstweilige Maßnahmen
- Parteien
- Kläger
- Teleflex Life Sciences II LLCUnternehmen
Vertreter- Ulrich Blumenröder-Grünecker Patent- und Rechtsanwälte PartGmbH
- Sebastian Ochs-Grünecker Patent- und Rechtsanwälte PartGmbH
- Elvira Bertram-Grünecker Patent- und Rechtsanwälte PartGmbH
- Thomas Laubenthal-Grünecker Patent- und Rechtsanwälte PartGmbH
- Alexander Stumvoll-Grünecker Patent- und Rechtsanwälte PartGmbH
Beklagte- Speed Care Mineral GmbHUnternehmen
Vertreter- Alexander Reetz-Wildanger Kehrwald Graf von Schwerin & Partner mbB
- Peter-Michael Weisse-Wildanger Kehrwald Graf von Schwerin & Partner mbB
- Eva-Maria Thörner-Wildanger Kehrwald Graf von Schwerin & Partner mbB
- Jan-Caspar Maiers-Wildanger Kehrwald Graf von Schwerin & Partner mbB
- Division
- Hamburg LD
- Technologie
- InstrumentsMedical technology
- Sprache
- English
- Erste Entscheidung
- 21. Feb. 2025
- EPA-Einspruch
- CARL FREUDENBERG KG Patente und Marken2011-08-04
| Einstweilige Verfügung erlassen | Median Tage bis zur ersten Entscheidung | |
|---|---|---|
| Gesamt-UPC | 54% (38/70) | 124 |
| Hamburg LD | Gesperrt | Gesperrt |
| Richter Sabine Klepsch | Gesperrt | Gesperrt |
| Richter Stefan Johansson | Gesperrt | Gesperrt |
| Richter Stefan Schilling | Gesperrt | Gesperrt |
| Richter Jeroen Meewisse | Gesperrt | Gesperrt |
Vor dem UPC: Teleflex Life Sciences II LLC (6 Verfahren)·Speed Care Mineral GmbH (6 Verfahren)
Dieser Streit umfasst 5 weitere Verfahren
UPC CoA 85/2026·UPC CFI 235/2025·UPC CFI 157/2025·UPC CFI 685/2024·UPC CFI 1849/2026
Starten Sie die kostenlose Testphase, um die Ausgänge zu sehen.
Weitere Verfahren: Hamburg LD·2024
- 2025-02-21Application for provisional measuresÖffentlich
Zusammenfassung: The Hamburg Local Division dismissed Teleflex Life Sciences II LLC's application for provisional measures against Speed Care Mineral GmbH regarding hemostatic wound-care products, because Teleflex failed to demonstrate with sufficient certainty that the attacked embodiment contained a 'binder' as required by the patent claims, and the burden of proof was not reversed.
Rechtsfragen anzeigen (3)
- Burden of proof for patent infringement in provisional measures proceedings
- Reversal of burden of proof threshold under Art. 62(2) UPCA and R. 209(2) RoP
- Sufficiency of evidence for presence of claimed 'binder' element
| Dokumenttitel | Datum | Öffentlich |
|---|---|---|
| FInalOrder | 2025-02-21 | Nicht öffentlich |
| Headnote-and-Keywords | 2025-02-21 | Nicht öffentlich |
| Measures_DecisionOutcome_Notification.pdf | 2025-02-21 | Nicht öffentlich |
| Order with grounds | 2025-02-21 | Nicht öffentlich |
| Order with grounds | 2025-02-21 | Öffentlich |
| Template-Order | 2025-02-21 | Nicht öffentlich |
| Order with grounds | 2025-02-21 | Nicht öffentlich |
| Closing workflow (ORD_5952_2025) | 2025-02-04 | Nicht öffentlich |
| Outcome of the Order | 2025-02-04 | Nicht öffentlich |
| Closing workflow | 2025-02-04 | Öffentlich |
Teleflex Life Sciences applied for a preliminary injunction against Speed Care Mineral's hemostatic wound-care products based on EP 2 077 811. The Hamburg Local Division dismissed the application because Teleflex failed to demonstrate with the required certainty that the attacked product contained a 'binder' as claimed, and the burden of proof was not reversed in the applicant's favour. Since infringement could not be established, the court did not need to assess patent validity or other PI requirements.
Burden of proof for patent infringement lies with applicant and is not reversed without sufficient prior indication of infringement
BeklagterRechtsgrundlage: Art. 62(2) UPCA; Rule 209(2) RoPHinweis: The Hamburg Local Division confirmed that the standard burden of proof on the applicant to establish infringement was not reversed in this case because Teleflex had not provided reasonable indications that the accused product contained a 'binder' as required by the claims.
Attacked embodiment (Speed Care hemostatic gauze) contains a binder as required by patent claims
KlägerRechtsgrundlage: EP 2 077 811Begründung: Teleflex failed to demonstrate with sufficient certainty that the attacked product contains a binder; the defendant's evidence (scanning electron microscope images from University of Greifswald) showed mechanical adhesion of halloysite to cellulose fiber without a binder, and Teleflex presented no contradicting evidence.
Burden of proof should be reversed because applicant has provided reasonable indications of infringement
KlägerRechtsgrundlage: Rule 209(2) RoPBegründung: The court found that the applicant's evidence was insufficient to constitute 'reasonable indications and/or facts' that would reverse the burden of proof.
The central claim construction issue was the meaning of 'binder' in EP 2 077 811 (clay-based hemostatic agents). The court did not resolve this definitively because it found infringement not proven regardless: the defendant argued that halloysite nanotubes mechanically adhere to the Lyocell carrier via interlacing and electrostatic processes without a binder, and Teleflex could not disprove this.